# PMV Pharmaceuticals, Inc.: overview PMVP · Nasdaq · CIK 1699382 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pmvp.md) · [Financials](/companies/pmvp/financials.md) · [Filings](/companies/pmvp/filings.md) · [Insiders](/companies/pmvp/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.37)](/filings/0001193125-25-276003.md) | not reported | [(0.34)](/filings/0001193125-26-218227.md) | [(0.41)](/filings/0001193125-26-350448.md) | [(0.40)](/filings/0001193125-25-276003.md) | not reported | [(0.34)](/filings/0001193125-26-218227.md) | [(0.34)](/filings/0001193125-26-350448.md) | | Free cash flow | $m | [(16.8) d](/filings/0001193125-25-276003.md) | [(16.7) d](/filings/0001193125-26-095014.md) | [(18.3)](/filings/0001193125-26-218227.md) | [(18.3) d](/filings/0001193125-26-350448.md) | [(19.8) d](/filings/0001193125-25-276003.md) | [(17.2) d](/filings/0001193125-26-095014.md) | [(19.7)](/filings/0001193125-26-218227.md) | [(14.6) d](/filings/0001193125-26-350448.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.28)](/filings/0000950170-24-023062.md) | [(1.61)](/filings/0000950170-25-030414.md) | [(1.44)](/filings/0001193125-26-095014.md) | [(1.14)](/filings/0001193125-26-095014.md) | [(1.48)](/filings/0001193125-26-095014.md) | | Free cash flow | $m | [(47.9)](/filings/0000950170-24-023062.md) | [(71.7)](/filings/0000950170-25-030414.md) | [(56.6)](/filings/0001193125-26-095014.md) | [(51.9)](/filings/0001193125-26-095014.md) | [(73.6)](/filings/0001193125-26-095014.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pmvp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $7.1m | 5,330,000 | | Added +10,000 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $5.7m | 4,245,085 | | Unchanged | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $3.5m | 2,634,137 | | Reduced −442,443 | | [Euclidean Capital LLC](/funds/1825034.md) | 2026-06-30 | $3.5m | 2,627,643 | | Unchanged | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $3.2m | 2,360,000 | | Added +500,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.7m | 2,012,020 | | Added +37,114 | | [ArrowMark Colorado Holdings LLC](/funds/1483859.md) | 2026-06-30 | $2.6m | 1,959,579 | | Reduced −913,185 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $2.6m | 1,954,136 | | Added +69,606 | | [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $2.5m | 1,890,904 | | Reduced −457,456 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.2m | 919,818 | | Added +45,444 | ## Recent filings [All 381 filings](/companies/pmvp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 13:00 ET | [8-K](/filings/0001193125-26-413254.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-413254 | | 2026-09-02 | 22:23 ET | [8-K](/filings/0001193125-26-378838.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-378838 | | 2026-08-31 | 20:06 ET | [8-K](/filings/0001193125-26-376723.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-376723 | | 2026-08-14 | 12:00 ET | [10-Q](/filings/0001193125-26-350448.md) | Quarterly report, period 2026-06-30 | 0001193125-26-350448 | | 2026-08-14 | 12:00 ET | [8-K](/filings/0001193125-26-350445.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-350445 | | 2026-06-05 | 12:10 ET | [8-K](/filings/0001193125-26-258466.md) | 5.07 Shareholder vote results | 0001193125-26-258466 | | 2026-05-12 | 12:00 ET | [10-Q](/filings/0001193125-26-218227.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218227 | | 2026-05-12 | 12:00 ET | [8-K](/filings/0001193125-26-218225.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218225 | | 2026-04-22 | 12:01 ET | [DEF 14A](/filings/0001140361-26-016038.md) | Proxy statement, period 2026-06-04 | 0001140361-26-016038 | | 2026-03-06 | 13:24 ET | [8-K](/filings/0001193125-26-095094.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-095094 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-095014.md), filed Mar 6, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1699382 - Tickers: PMVP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.